Archives
-
H3K18 Lactylation Drives NOD2 in Bilirubin Injury
2026-09-12
Li et al. identify an immunometabolic mechanism linking bilirubin exposure to astrocyte pyroptosis: glycolysis-associated H3K18 lactylation increases NOD2 transcription and amplifies MAPK and NF-κB signaling. The findings position the H3K18la/NOD2 axis as a mechanistic connection between altered metabolism, epigenetic regulation, and neuroinflammation in bilirubin encephalopathy.
-
KN-62: Mapping CaMKII Control of Calcium Signals
2026-09-11
KN-62 is a selective CaMKII inhibitor for dissecting calcium-dependent signaling, secretion, metabolism, and cell-cycle behavior. This guide connects its pharmacology with modern flux-aware assay design inspired by autophagy research.
-
Ziprasidone, GOT1, and PDAC Metabolic Reprogramming
2026-09-11
The reference study identifies ziprasidone as a non-competitive inhibitor of GOT1 and connects enzyme inhibition with glutamine-metabolism disruption, redox imbalance, and reduced pancreatic ductal adenocarcinoma growth. Its integrated biochemical, cellular, metabolomic, and xenograft design provides a useful framework for evaluating metabolism-directed PDAC therapies while also highlighting the need for target-engagement and resistance studies.
-
LNP Charge and V-ATPase Drive Nucleic Acid Tropism
2026-09-10
The reference study proposes that LNP surface charge and target-cell V-ATPase activity jointly determine functional nucleic acid delivery, rather than treating nanoparticle properties as the sole driver of tropism. Its in vitro, in vivo, perturbation, and protein-corona analyses connect charge-dependent biodistribution with intracellular endo/lysosomal processing and suggest practical variables for delivery studies.
-
5X Protein Loading Buffer (Reducing) Guide
2026-09-10
5X Protein Loading Buffer (Reducing), SKU K1164, prepares protein samples for conventional denaturing SDS-PAGE by combining SDS, a sulfhydryl reducing agent, buffer salts, and bromophenol blue. It is appropriate for reducing protein molecular weight separation, but not for native analyses or workflows that must preserve disulfide bonds and native conformation.
-
Nystatin (Fungicidin): Mechanism and Research Guide
2026-09-09
Nystatin, also called Fungicidin, is a polyene antifungal that targets ergosterol-containing fungal membranes. Product-reported benchmarks support research on Candida adhesion, Aspergillus infection models, formulation behavior, and sterol-dependent membrane disruption, but they do not establish a clinical regimen.
-
Acifran: GPCR Assays for Lipid Metabolism
2026-09-09
Acifran enables paired HCAR2/GPR109A and HCAR3/GPR109B experiments that connect receptor activation with Gi-linked cAMP signaling. This workflow combines practical compound handling, matched receptor comparisons, and structural insight for more reproducible lipid metabolism research.
-
Epinephrine Bitartrate: Adrenergic Research Guide
2026-09-08
Epinephrine Bitartrate is a non-selective adrenergic receptor agonist used to study alpha- and beta-receptor signaling. Its reported receptor activity, assay applications, formulation properties, and translational limits support controlled work in cardiovascular disease research, sympathetic nervous system research, and cell-function assays.
-
SVA 3A/2B Proteins Counteract DDX23 via Caspases
2026-09-08
The reference study identifies a dual antagonistic interaction in which host DDX23 restricts Senecavirus A (SVA), while viral 3A and 2B proteins redirect caspase-dependent degradation toward DDX23 or viral proteins. Its combination of protein perturbation, caspase-pathway analysis, residue mapping, and reverse genetics provides a framework for studying SVA immune evasion and for designing mechanistically controlled apoptosis experiments.
-
LNP Surface Charge and V-ATPase Drive Nucleic Acid Delivery
2026-09-07
The reference study proposes that lipid nanoparticle tropism is determined not only by particle surface charge but also by the V-ATPase activity of recipient cells. Its in vitro and in vivo experiments link this interaction to serum-dependent delivery, liver-versus-lung distribution, reticuloendothelial-system conditioning, and differences in protein corona composition.
-
Chenodeoxycholic Acid: A Causal FXR Assay Framework
2026-09-07
Chenodeoxycholic Acid (CDCA) is a powerful probe for connecting FXR activation with transcriptional and injury-response phenotypes. This article presents a causal assay framework grounded in the FXR–KLF11–JAK2/STAT3 axis and practical compound-handling requirements.
-
Clathrin-Mediated Entry of Type III Grass Carp Reovirus
2026-09-05
Wang et al. used inhibitor profiling, transmission electron microscopy, and quantitative PCR to show that genotype III grass carp reovirus GCRV104 enters grass carp kidney cells through a dynamin-dependent, clathrin-mediated and endosomal pH-dependent route. The study provides a mechanistic framework for comparing GCRV genotypes and for evaluating entry inhibitors, while also highlighting the limitations of inferring viral pathways from pharmacological perturbations alone.
-
Cy3 TSA Fluorescence System Kit for p53-R280K
2026-09-04
The Cy3 TSA Fluorescence System Kit enables sensitive spatial analysis of the p53-R280K/SREBP1/FASN axis. Learn how TSA chemistry can strengthen mechanistic studies of lipid-driven breast cancer progression while preserving assay rigor.
-
BKT140 (BL-8040): CXCR4 Assay Strategy
2026-09-04
BKT140, also known as BL-8040 and TF 14016, is a CXCR4 antagonist for dissecting chemotaxis, tumor–microenvironment interactions, apoptosis, and stem cell mobilization. This article presents a decision-centered assay framework that connects CXCR4 biology with practical oncology research workflows.
-
VE-822 ATR Inhibitor: Assay Workflow Guide
2026-09-03
VE-822 is a potent ATR inhibitor for connecting replication-stress biology with practical radiosensitization and gemcitabine-combination assays. This guide translates its PDAC research value into a controlled workflow, while adapting the personalized prescreening logic of an iPSC reference study without overstating cross-domain evidence.